Hofseth Biocare ASA banner

Hofseth Biocare ASA
OSE:HBC

Watchlist Manager
Hofseth Biocare ASA Logo
Hofseth Biocare ASA
OSE:HBC
Watchlist
Price: 1.41 NOK -1.05%
Market Cap: kr557.1m

Wall Street
Price Targets

HBC Price Targets Summary
Hofseth Biocare ASA

There are no price targets for HBC.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Hofseth Biocare ASA Competitors:
Price Targets
KRNY
Kearny Financial Corp
13% Upside
FLB
Fluidigm Corp
71% Upside
BTBT
Bit Digital Inc
304% Upside
AFYA
Afya Ltd
13% Upside
BLIN
Bridgeline Digital Inc
435% Upside
STG
Strip Tinning Holdings PLC
149% Upside

Revenue
Forecast

47% / Year
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss
47% / Year
Past Growth
-7% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss

For the last 14 years the compound annual growth rate for Hofseth Biocare ASA's revenue is 47%. The projected CAGR for the next 10 years is -7%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
99%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
99%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-68%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-68%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HBC's stock price target?
Not Available

HBC doesn't have any price targets made by Wall Street professionals.

What is Hofseth Biocare ASA's Revenue forecast?
Projected CAGR
-7%

For the last 14 years the compound annual growth rate for Hofseth Biocare ASA's revenue is 47%. The projected CAGR for the next 10 years is -7%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett